We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
-2.5%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$214M
AUM Growth
–
Cap. Flow
+$230M
Cap. Flow %
107.56%
Top 10 Hldgs %
83.52%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$28.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$24.5M
3
COGT icon
Cogent Biosciences
COGT
+$23.9M
4
CBAY
Cymabay Therapeutics
CBAY
+$22.4M
5
TYRA icon
Tyra Biosciences
TYRA
+$16.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$29.1M 13.63%
+1,741,228
New +$28.5M
VRDN icon
2
Viridian Therapeutics
VRDN
$2.61B
$26M 12.16%
+1,314,000
New +$24.5M
COGT icon
3
Cogent Biosciences
COGT
$6.02B
$23.6M 11.05%
+2,750,037
New +$23.9M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$20M 9.35%
+5,905,400
New +$22.4M
ALPN
5
DELISTED
Alpine Immune Sciences Inc
ALPN
$16.2M 7.59%
+1,170,212
New +$14.5M
ACRS icon
6
Aclaris Therapeutics
ACRS
$885M
$15.7M 7.37%
+1,082,213
New +$16.4M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14.4M 6.74%
+882,353
New +$12.6M
TYRA icon
8
Tyra Biosciences
TYRA
$1.49B
$12M 5.6%
+850,450
New +$16.9M
TRDA icon
9
Entrada Therapeutics
TRDA
$273M
$11.4M 5.32%
+663,694
New +$16.1M
JBIO
10
Jade Biosciences
JBIO
$1.33B
$10.1M 4.71%
+24,381
New +$12.3M
DNTH icon
11
Dianthus Therapeutics
DNTH
$5.92B
$9.84M 4.61%
+138,889
New +$14M
AKUS
12
DELISTED
Akouos Inc
AKUS
$8.88M 4.16%
+1,045,215
New +$9.37M
MRUS
13
DELISTED
Merus
MRUS
$7.16M 3.35%
+225,000
New +$6.36M
ZLAB icon
14
Zai Lab
ZLAB
$2.93B
$5.97M 2.8%
+95,000
New +$8.06M
ELEV
15
DELISTED
Elevation Oncology
ELEV
$3.34M 1.56%
+555,000
New +$3.83M

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for TCG Crossover Management, which disclosed 15 positions worth $214M. Its ten largest holdings account for 84% of the portfolio.

Its largest position is IVERIC bio, Inc. Common Stock: 1,741,228 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • TCG Crossover Management's largest Q4 2021 buy was IVERIC bio, Inc. Common Stock: 1,741,228 shares worth $29.1M.
  • TCG Crossover Management's ten largest holdings make up 84% of its $214M portfolio in Q4 2021.
  • TCG Crossover Management disclosed 15 positions in Q4 2021, its first 13F filing on record.

Based on TCG Crossover Management's 13F filing for Q4 2021, filed 18 Feb 2022.